Journals / Annals of Medical Research / 2020 / Cilt: 27 - Sayı: 1

An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome

Pages
1–6
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Chronic inflammation may be multifactorial in PCOS and there is a need for studies with larger sample sizes to be ableto explain the exact role of inflammatory markers in PCOS etiology

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The aim of this study was to evaluate new and current inflammatory markers in women with polycystic ovary syndrome (PCOS)and to clarify the role of these markers in the etiopathogenesis of PCOS.Material and Methods: This retrospective study included 97 women with PCOS and 124 body mass index-matched controls withoutPCOS.
📊
Key Findings & Data:The parameters examined as new and current markers in both groups were the monocyte-to-high density lipoproteincholesterol (HDL-C) ratio, high sensitivity C-reactive protein/ albumin ratio, systemic immune-inflammation index, inflammatoryprognostic index, prognostic nutritional index, white blood cell count, mean platelet volume, platelet distribution width, plateletcrit,neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, triglycerides to HDL-C ratio and the lipid accumulation product index.Results: No significant difference was found between the PCOS and control group in respect of inflammatory markers.
💡
Conclusion & Impact:Chronic inflammation may be multifactorial in PCOS and there is a need for studies with larger sample sizes to be ableto explain the exact role of inflammatory markers in PCOS etiology
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: The aim of this study was to evaluate new and current inflammatory markers in women with polycystic ovary syndrome (PCOS)and to clarify the role of these markers in the etiopathogenesis of PCOS.Material and Methods: This retrospective study included 97 women with PCOS and 124 body mass index-matched controls withoutPCOS. The parameters examined as new and current markers in both groups were the monocyte-to-high density lipoproteincholesterol (HDL-C) ratio, high sensitivity C-reactive protein/ albumin ratio, systemic immune-inflammation index, inflammatoryprognostic index, prognostic nutritional index, white blood cell count, mean platelet volume, platelet distribution width, plateletcrit,neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, triglycerides to HDL-C ratio and the lipid accumulation product index.Results: No significant difference was found between the PCOS and control group in respect of inflammatory markers. The age andfollicle-stimulating hormone values of PCOS patients were found to be lower than those of the control group. Luteinizing hormone,free androgen index, insulin and the homeostasis model assessment of insulin resistance values of PCOS patients were significantlyhigher than those of the control group.Conclusion: In terms of inflammatory parameters, no significant difference was determined between patients with PCOS and thecontrol group. Chronic inflammation may be multifactorial in PCOS and there is a need for studies with larger sample sizes to be ableto explain the exact role of inflammatory markers in PCOS etiology

🔖

Cite This Article

ARPACI, H. (2022). An evaluation of new and current inflammatory markers in patients with polycystic ovary syndrome. Annals of Medical Research, Cilt: 27 - Sayı: 1, 1–6. https://ajindex.com/articles/446448

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7
  2. Azziz R, Carmina E, Dewailly D, et al. The androgen excess and pcos society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456-88
  3. Ojeda-Ojeda M, Murri M, Insenser M, et al. Mediators of lowgrade chronic inflammation in polycystic ovary syndrome (PCOS). Curr Pharm Des 2013;19:5775-91
  4. Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol 2011;335:30-41
  5. Zahorec R. Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001;102:5-14
  6. Margolis KL, Manson JE, Greenland P, et al. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women’s Health Initiative Observational Study. Arch Intern Med 2005;165:500-8
  7. Yuri Gasparyan A, Ayvazyan L, P Mikhailidis D, et al. Mean platelet volume: a link between thrombosis and inflammation?. Curr Pharm Des 2011;17:47-58
  8. Balta S, Celik T, Mikhailidis DP, et al. The relation between atherosclerosis and the neutrophil–lymphocyte ratio. Clin Appl Thromb Hemost 2016;22:405-11
  9. Balta S, Ozturk C. The platelet-lymphocyte ratio: a simple, inexpensive and rapid prognostic marker for cardiovascular events. Platelets 2015;26:680-1
  10. Kim MH, Ahn JY, Song JE, et al. The C-reactive protein/ albumin ratio as an independent predictor of mortality in patients with severe sepsis or septic shock treated with early goal-directed therapy. PLoS One 2015;10:e0132109
  11. Kanbay M, Solak Y, Unal HU, et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int Urol Nephrol 2014;46:1619-25
  12. Cetin MS, Cetin EHO, Kalender E, et al. Monocyte to HDL cholesterol ratio predicts coronary artery disease severity and future major cardiovascular adverse events in acute coronary syndrome. Heart Lung Circ 2016;25:1077-86
  13. Armato J, Reaven G, Ruby R. Triglyceride/high-density lipoprotein cholesterol concentration ratio identifies accentuated cardio-metabolic risk. Endocr Pract 2015:1-18
  14. Wiltgen D, Benedetto IG, Mastella LS, et al. Lipid accumulation product index: a reliable marker of cardiovascular risk in polycysti